No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.
www.mizuho-m.co.jpNo one on the platform currently holds 4595.T.
No tracked institution reports a position in 4595.T as of their last filing.
No one on the platform has traded 4595.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 42.8% | 84.6% | 52.2% | — | — | — |
| Rev. Growth % | -1.5% | 21.8% | ||||
| Profit Margin % | 30.4% | 35.9% | 23.5% | |||
| Free Cash Flow Margin % | 15.1% | 30.4% | 17.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.9B | -4.0% | $152.20 | $152.20–$152.20 | — | 1 |
| 2027 | $11.4B | +4.6% | $160.10 | $160.10–$160.10 | — | 1 |
| 2028 | $11.9B | +4.4% | $168.00 | $168.00–$168.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.00% |
| $14.2B |
| — |
| 4577.TDaito Pharmaceutical Co.,Ltd. | $1289.00 | +1.34% | $37.1B | — |
| 5592.TKusurinomadoguchi, Inc. | $2694.00 | -0.99% | $30.9B | — |
Source: Financial Modeling Prep · peers by sector/industry